https://charts.traderzeitung.de/phases/US81642T2096
string(1514) "{"isin":"US81642T2096","name":"SELLAS Life Sciences Group Inc","stock_id_xnas":10463971,"stock_id_xnys":null,"generated_at":"2026-08-20 22:27:00","days":[{"date":"2026-08-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":12.87,"close_at":"2026-08-18 14:50:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.095,"close_at":"2026-08-18 21:59:00","complete":true,"perf_pct":1.7483},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":13.07,"close_at":"2026-08-19 01:12:00","complete":true,"perf_pct":-0.1909}]},{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":13.37,"close_at":"2026-08-19 15:20:00","complete":true,"perf_pct":2.2953},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.855,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":3.6275},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":14.11,"close_at":"2026-08-20 01:51:00","complete":true,"perf_pct":1.8405}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":13.89,"close_at":"2026-08-20 15:29:00","complete":true,"perf_pct":-1.5592},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.405,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-3.4917},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"
SELLAS Life Sciences Group Aktie News & Nachrichten

SELLAS Life Sciences Group Aktie News & Nachrichten

[WKN: A2PU3T | Symbol: SLS]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

SELLAS Life Sciences Group (SLS) im Pivotal-Point-Check: Aussicht auf bahnbrechende Überlebensdaten bei AML sorgt für 18 % Kursfeuerwerk!

Fortgeschrittene Krebsstudie: Das wichtigste Medikament Galinpepimut-S (GPS) steht unmittelbar vor...

SELLAS Life Sciences: Diese Phase-3-Daten könnten alles verändern

SELLAS Life Sciences Group ist ein US-amerikanisches Biotechnologieunternehmen im Spätstadium der klinischen...

  • 1
MT Newswires 11.08.2026 22:50 Uhr

Sellas Life Sciences verringert Verlust im Q2

04:49 PM EDT, 11.08.2026 (MT Newswires) -- Sellas Life Sciences (SLS) meldete am späten Dienstag einen Verlust im Q2 von 0,05 US-Dollar je verwässerte

MT Newswires 11.08.2026 22:32 Uhr

-- Earnings Flash (SLS) SELLAS Life Sciences verzeichnet Q2 Verlust von 0,05 USD, gegenüber FactSet-Schätzung von 0,05 Verlust

04:31 PM EDT, 11.08.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 29.06.2026 12:42 Uhr

Sozialer Buzz: Wallstreetbets-Aktien steigen vorbörslich am Montag; SELLAS Life Sciences, Strategy werden höher eröffnen

06:40 AM EDT, 06/29/2026 (MT Newswires) -- Die meistdiskutierten Aktien im Reddit-Subforum Wallstreetbets stiegen Stunden vor der Eröffnungsglocke am